실크피브로인을 처리한 MC3T3-E1 조골세포 조건배양액의 파골세포 분화억제효과

국문 초록 (Abstract)

본 연구는 MC3T3-E1 조골전구세포에 실크피브로인 처리 시 파골세포분화 관련 국소인자 중 파골세포로의 분화를 강력히 유도하는 IL-1β의 발현 및 파골세포로의 분화억제에 관여하는 국소인자인 OPG의 발현변화를 조골세포 조건배양액에서 살펴보았으며, 이 조골세포 조건배양액을 RAW264.7 파골전구세포에 처리 시 파골세포로의 분화를 억제하는지를 알아보았다. 조골세포 조건배양액에서 OPG의 발현은 농도별(0.001 ㎎/mL～0.1 ㎎/mL) 실크피브로인 처리 시 86%～100%로 양성대조군(+C)과 유의적 차이가 없었다. 그러나 IL-1β의 발현은 0.1 ㎎/mL 실크피브로인 처리 시 양성대조군(+C)의 1.8% 수준으로 그 발현을 현저히 억제 하였다. 조골세포조건배양액을 처리한 RAW264.7 세포의 파골세포로의 분화정도는 농도 의존적으로 현저히 감소하였다. 특히, 0.1 ㎎/mL의 실크피브로인을 처리한 조골세포 조건배양액 처리 시 파골세포로 분화하지 않은 음성대조군(-RANKL) 수준으로 파골세포 분화를 현저히 억제한 것은 OPG의 발현 증가가 아닌 IL-1β의 발현 억제에 의한 것으로 사료되며, 추후 연구를 통해 관련 기전의 연구가 필요할것으로 생각되어진다.

다국어 초록 (Multilingual Abstract)

In this study, we investigated the indirect effect of silk-fibroin on osteoclastic differentiation of RAW264.7 cells. The conditioned medium were collected from MC3T3-E1 osbeoblasts treated with 0.001 ㎎/mL～0.1 ㎎/mL silk fibroin for 6 days, mixed in 1:1 ratio with osteoclast medium, and then added into RAW264.7 cells with receptor activator of nuclear factor kappa B ligand (RANKL), a differentiation inducer for 3 days. Of osteoclastic cytokines in the conditioned medium, the protein expression of osteoprotegerin (OPG) with silk-fibroin was not significantly different. However, the protein expression of interleukin (IL)-1β was specifically lower in a dose dependent manner. In RAW264.7 cells, the conditioned medium with silk-fibroin inhibited RANKL induced osteoclastic differentiation as total number of multinucleated tartrate-resistant alkaline phosphatase (TRAP)-positive osteoclasts in a dose dependent manner. Taken together, we demonstrated that the conditioned medium of silk-fibroin treated osteoblasts inhibits RANKL induced differentiation of osteoclasts with inhibiting selective expression of IL-1β.

목차 (Table of Contents)

• Abstract
• 서론
• 재료 및 방법
• 결과 및 고찰
• 요약
• 감사의 글
• 문헌

참고문헌 (Reference)

1 Arnett TR, "Update on bone cell biology" 12 : 81-90, 1990

2 Hotokezaka H, "U0126 and PD98059, specific inhibition of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells" 277 : 47366-47372, 2002

3 Fanti P, "The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats" 8 : 274-281, 1998

4 Mok SK, "The effects of prostaglandine and dibutylryl cAMP on osteoblastic cell activity and osteoclast generation" 6 : 43-62, 1996

5 Yeo JH, "The effect of PVA/chitosan/fibroin (PCF)-blended sponge on wound healing in rats" 23 : 1220-1223, 2000

6 Thomas C, "The actions and interactions of sex steroids and growth factors/cytokines on the skeleton" 13 : 819-828, 2005

7 Khosla S, "The OPG/RANKL/RANK system" 142 : 5050-5055, 2001

8 Kurolouchi K, "TNF-α increases expression of IL-6 and ICAM-1 genes through activation of NK-κB in osteoblast-like ROS17/2.8 cells" 13 : 1290-1299, 1998

9 Gregory HA, "Silk-based biomaterials" 24 : 401-416, 2003

10 Baker VL, "Selective estrogen receptor modulators in reproductive medicine and biology" 55 : 21-47, 2000

11 Chambers TJ, "Regulation of the differentiation and function of osteoclasts" 192 : 4-13, 2000

12 Chaudhary LR, "Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1β and tumor necrosis factor-α: lack of regulation by 17β-estradiol" 130 : 2528-2534, 1992

13 Aldercreutz H, "Phyto-oestrogens in relation to cancer and other human health risks" 55 : 399-417, 1996

14 Lorenz CH, "Osteoprotegerin: a novel local player in bone metabolism" 137 : 345-346, 1997

15 Kong YY, "Osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis" 44 : 253-259, 2001

16 Parfitt AM, "Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone" 55 : 273-286, 1994

17 Yasuda H, "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL" 95 : 3597-3602, 1998

18 Jilka RL, "Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines" 13 : 793-802, 1998

19 Udagawa N, "Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepaared by bone marrow-derived stromal cells" 87 : 7260-7264, 1990

20 Evans DM, "Nitric oxide and bone" 11 : 300-305, 1996

21 Kim DK, "Neuroprotection and enhancement of learning and memory by BF-7" 51 : 317-324, 2005

22 Madyarov S, "Improved method for the preparation of silk fibroin hydrolysates" 41 : 102-110, 2000

23 Kang SA, "High performance liquid chromatographic analysis of isoflavones in soybean and blackbean" 8 : 44-48, 2001

24 Susan S, "Functionalized silk-based biomaterials for bone formation" 54 : 139-148, 2001

25 Yeo JH, "Fractionation of a silk fibroin hydrolysate and its protective function of hydrogen peroxide toxicity" 102 : 772-776, 2006

26 Helfrich MH, "Expression of nitric oxide synthase isoforms in bone and bone cell cultures" 12 : 1108-1115, 1997

27 Keeting PE, "Evidence for interleukin-1 production by cultured normal human osteoblast-like cells" 6 : 827-833, 1991

28 Rogers J, "Estrogens in the menopause and postmenopause" 280 : 364-367, 1967

29 Kameda T, "Estrogen inhibits bone resorption by directly inducing apoptosis of the bone resorbing osteoclasts" 186 : 489-495, 1997

30 Li C, "Electrospun silk-BMP-2 scaffolds for bone tissue engineering" 27 : 3115-3124, 2006

31 Smith DD, "Effects of interferon-gamma and other cytokines in collagen synthesis in fetal rat bone cultures" 120 : 2494-2499, 1987

32 Tobias JH, "Does estrogen stimulate osteoblast function in postmenopausal women?" 24 : 121-124, 1999

33 Jilka RL, "Cytokines, bone remodeling, and estrogen deficiency: a 1998 update" 23 : 75-81, 1998

34 Sugimoto E, "Anabolic effect of genistein in osteoblastic MC3T3-E1 cells" 5 : 515-520, 2000

35 Gray TK, "17β- estradiol acts directly on the clonal osteoblast cell line UMR106" 84 : 6267-6271, 1987